查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081978

新抗原標標靶治療市場：2026-2032 年全球市場預測，依治療方法、治療途徑、給藥途徑、年齡層、目標疾病和最終用戶分類。

Neoantigen Targeted Therapies Market by Therapy Modality, Treatment Approach, Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，新抗原標靶治療市場將成長至 156.1 億美元，複合年成長率為 16.66%。

主要市場統計數據
基準年 2025 53億美元
預計年份：2026年 61.5億美元
預測年份 2032 156.1億美元
複合年成長率 (%) 16.66%

以新抗原為標靶治療正在革新精準腫瘤學，其核心在於辨識腫瘤特異性突變，而這些突變通常不會出現在正常組織中。這種方法支持高度個人化的癌症疫苗、過繼性T細胞療法、T細胞受體療法以及旨在誘導針對患者特異性或通用腫瘤抗原的免疫反應的聯合治療。

次世代定序、 HLA型檢測、免疫胜肽體學和先進的生物資訊技術能夠更快、更可靠地鑑定出可行的腫瘤新抗原候選物，從而加速該領域的發展。儘管臨床開發仍然複雜，但科學證據確鑿，因為腫瘤新抗原有望增強腫瘤特異性、促進免疫記憶，並提供不同於傳統化療和廣譜生物製藥的新型治療途徑。

新抗原療法的前景發生了變革性變化

新抗原標靶治療的格局正從探索性的免疫腫瘤學研究轉向可擴展的轉化平台。全EXOME定序、RNA定序、單細胞分析和腫瘤微環境分析技術的進步，使研發人員能夠選擇更具臨床意義的表位，並在商業性價值的時間範圍內設計個人化療法。

人工智慧對新抗原發現的累積影響

人工智慧在新抗原的發現、優先排序和生產設計中發揮核心作用。人工智慧驅動的流程可以透過整合腫瘤DNA和RNA定序、HLA結合預測、克隆性評估、抗原加工訊號和免疫抗原性模型，減少進入高成本的檢驗流程的低價值候選抗原的數量。

針對新抗原的標靶治療的關鍵區域性見解

北美地區仍然是新抗原標靶治療的領先地區，這得益於該地區聚集了許多腫瘤領域的生物技術公司、大學附屬癌症中心、合約開發合作夥伴和創業投資資金。憑藉FDA監管的臨床試驗活動、腫瘤醫學中廣泛應用的定序技術以及強大的轉化研究網路，美國處於這一生態系統的核心地位；而加拿大則透過癌症基因組學、免疫療法研究和公共資助的醫療創新計畫做出貢獻。

全球創新模組的關鍵群體特定見解

在主要經濟和地緣政治集團中，七國集團憑藉其先進的臨床試驗體系、大規模的生物醫學研究經費、強大的腫瘤治療能力和豐富的監管經驗，在新抗原標靶治療佔據著舉足輕重的地位。北約成員國與主要的生物醫學創新中心高度重合，這有利於開展合作研究、建立穩健的供應鏈、建立低溫運輸物流以及採用標準化方法處理先進療法。

主要國家新抗原標靶治療引入狀況分析

美國憑藉其先進的腫瘤臨床試驗體系、雄厚的創業投資基礎、成熟的先進療法法規結構以及完善的高價值精準醫療報銷管道，在全球新抗原標靶治療的商業化潛力方面處於領先地位。加拿大則憑藉其癌症基因組學研究和公共資助的臨床網路與之形成互補。墨西哥和巴西是重要的拉丁美洲市場，日益加重的癌症負擔和私人醫療保健體系的擴張將推動未來新抗原標靶療法的普及，但前提是能夠更便捷地獲得分子診斷、切片檢查物流和專業的癌症治療服務。

為行業領導者提供的實用建議

產業領導者應優先考慮整合腫瘤定序、 HLA型檢測、轉錄組學、Peptidomics學和檢驗的人工智慧模型的綜合發現平台。競爭優勢將源於快速識別臨床相關新抗原、確保個人化產品生產以及透過可靠的生物標記證據證明免疫活化的能力。

調查方法

本調查方法採用結構化的二手研究途徑。分析整合了來自監管機構、同行評審的腫瘤學文獻、臨床試驗註冊資料庫、政府醫療保健計畫、大學癌症中心出版物和認可的科學組織的資訊。

結論

新抗原標靶治療是癌症免疫治療領域最精準、最前線的研究方向之一。定序、計算生物學、人工智慧和先進製造技術的融合，提高了個人化、高特異性治療策略的可行性，該領域正持續發展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：新抗原標靶治療市場：依治療方法分類

  • 過繼性細胞療法
    • CAR-T細胞療法
    • T細胞受體（TCR）療法
    • 腫瘤浸潤淋巴細胞（TILs）
  • 個人化新抗原疫苗
    • 樹突狀細胞（DC）疫苗
    • DNA/RNA疫苗
    • 胜肽（SLP）疫苗

第8章：新抗原標靶治療市場：依治療方法分類

  • 聯合治療
  • 單藥治療

第9章：新抗原標靶治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下

第10章：新抗原標標靶治療市場：依年齡層分類

  • 成人
  • 老年人
  • 兒童

第11章 新抗原標靶治療市場：以標靶疾病分類

  • 骨癌
  • 結腸癌
  • 婦科癌症
  • 非小細胞肺癌
  • 腎臟細胞癌

第12章：新抗原標靶治療市場：依最終用戶分類

  • 學術和政府附屬研究機構
  • 醫院和診所
  • 專科診所

第13章：新抗原標靶治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：新抗原標靶治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：新抗原標靶治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CureVac NV
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics NV
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd
Product Code: MRR-43078BB92C77

The Neoantigen Targeted Therapies Market is projected to grow by USD 15.61 billion at a CAGR of 16.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.30 billion
Estimated Year [2026] USD 6.15 billion
Forecast Year [2032] USD 15.61 billion
CAGR (%) 16.66%

Neoantigen targeted therapies are reshaping precision oncology by focusing on tumor-specific mutations that are generally absent from healthy tissue. This approach supports highly individualized cancer vaccines, adoptive T-cell therapies, T-cell receptor programs, and combination regimens designed to direct immune activity toward patient-specific or shared tumor antigens.

The field is gaining momentum because next-generation sequencing, HLA typing, immunopeptidomics, and advanced bioinformatics can now identify actionable neoantigen candidates with greater speed and confidence. Clinical development remains complex, but the scientific rationale is strong: neoantigens can improve tumor specificity, support immune memory, and provide a differentiated path beyond conventional chemotherapy and broadly targeted biologics.

Transformative Shifts in the Neoantigen Therapy Landscape

The neoantigen targeted therapies landscape is shifting from exploratory immuno-oncology research toward scalable translational platforms. Improvements in whole-exome sequencing, RNA sequencing, single-cell analysis, and tumor microenvironment profiling are enabling developers to select more clinically relevant epitopes and design personalized therapies within commercially meaningful timelines.

Another major shift is the movement from single-modality development to rational combinations. Neoantigen vaccines and engineered cellular therapies are increasingly evaluated with immune checkpoint inhibitors, cytokine modulation, lymphodepletion strategies, or tumor microenvironment interventions. This reflects a growing recognition that antigen identification alone is not sufficient; durable response depends on antigen presentation, T-cell fitness, immune infiltration, and resistance management.

Cumulative Impact of Artificial Intelligence in Neoantigen Discovery

Artificial intelligence is becoming central to neoantigen discovery, prioritization, and manufacturing design. AI-enabled pipelines can integrate tumor DNA and RNA sequencing, HLA binding predictions, clonality assessment, antigen processing signals, and immunogenicity models to reduce the number of low-value candidates entering expensive validation workflows.

The cumulative impact of AI is also visible in clinical operations. Predictive analytics can support patient selection, trial stratification, toxicity monitoring, and adaptive protocol design. While AI models require rigorous validation across diverse HLA backgrounds and tumor types, they are accelerating the transition from data-heavy discovery to decision-ready therapeutic development.

Key Regional Insights for Neoantigen Targeted Therapies

North America remains a leading region for neoantigen targeted therapies due to its concentration of oncology biotechnology companies, academic cancer centers, contract development partners, and venture financing. The United States anchors this ecosystem through FDA-regulated clinical trial activity, broad sequencing adoption in oncology care, and strong translational research networks, while Canada contributes through cancer genomics, immunotherapy research, and publicly supported health innovation programs.

Europe benefits from established biopharmaceutical infrastructure, centralized regulatory engagement through the European Medicines Agency, and strong national oncology research systems across Germany, France, Italy, Spain, and the United Kingdom. The European Union's emphasis on health data governance and cross-border research can support multi-country trials, although reimbursement diversity, advanced therapy manufacturing capacity, and national health technology assessment requirements remain key considerations.

Asia-Pacific is expanding as China, Japan, South Korea, Australia, India, and ASEAN markets invest in precision medicine, clinical trial capacity, cancer genomics, and cell and gene therapy infrastructure. Latin America, led by Brazil and Mexico, offers growing oncology demand and improving clinical research participation, but access to advanced molecular diagnostics remains uneven across public and private care settings. The Middle East, especially GCC countries, is investing in genomics, specialty care, and tertiary oncology centers, while Africa represents an emerging opportunity where partnerships, pathology modernization, sequencing infrastructure, and equitable access models will determine long-term adoption.

Key Group Insights Across Global Innovation Blocs

Among major economic and geopolitical groups, the G7 holds a strong position in neoantigen targeted therapies because members combine advanced clinical trial systems, major biomedical research funding, high oncology care capacity, and deep regulatory experience. NATO countries overlap significantly with leading biomedical innovation hubs, supporting collaborative research, resilient supply chains, cold-chain logistics, and standardized approaches to advanced therapy handling.

The European Union is strategically important because it links scientific scale with harmonized regulatory pathways, clinical research networks, and data protection standards, creating a structured environment for multi-country oncology development. BRICS economies, particularly China, India, and Brazil, are increasingly relevant due to large patient populations, expanding sequencing capacity, and growing biomanufacturing capabilities, although regulatory maturity, reimbursement pathways, and access to high-complexity diagnostics vary by country.

ASEAN is becoming more attractive for clinical partnerships as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines improve oncology infrastructure, digital health adoption, and regional research connectivity. The GCC is also gaining importance through national genomics initiatives, investment in cancer centers, and demand for high-value precision oncology, creating opportunities for diagnostic-enabled therapy partnerships and specialized treatment pathways.

Key Country Insights in Neoantigen Targeted Therapy Adoption

The United States leads global commercialization potential for neoantigen targeted therapies through its advanced oncology trial ecosystem, strong venture capital base, mature regulatory framework for advanced therapies, and established reimbursement channels for high-value precision medicine. Canada complements this with cancer genomics research and publicly funded clinical networks. Mexico and Brazil are important Latin American markets where rising cancer burden and expanding private healthcare capacity support future adoption, provided molecular diagnostics, biopsy logistics, and specialized oncology access become more consistent.

In Europe, the United Kingdom, Germany, and France are prominent due to established oncology research centers, biopharma investment, genomic medicine programs, and strong clinical trial activity. Italy and Spain contribute meaningful patient recruitment capacity and specialist oncology networks, while Russia maintains scientific capabilities but faces operational and geopolitical constraints that can complicate international collaboration, technology transfer, and trial execution.

Across Asia-Pacific, China is a major force because of scale, domestic biotech growth, and investment in cell therapy, genomics, and oncology innovation. Japan and South Korea offer sophisticated regulatory systems, advanced hospitals, and strong biomanufacturing capabilities. India is increasingly relevant due to its large cancer population, expanding genomics sector, and cost-efficient clinical research environment. Australia has become a preferred early-phase oncology trial destination supported by high-quality sites, R&D incentives, experienced investigators, and strong translational research capacity.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated discovery platforms that combine tumor sequencing, HLA typing, transcriptomics, immunopeptidomics, and validated AI models. Competitive advantage will come from the ability to identify clinically relevant neoantigens quickly, manufacture individualized products reliably, and prove immune activation with robust biomarker evidence.

Organizations should also build combination strategies early, particularly with checkpoint inhibitors and tumor microenvironment modulators, while designing trials around measurable residual disease, adjuvant settings, and tumor types with high mutational burden. Strategic partnerships with sequencing providers, academic cancer centers, CDMOs, and real-world data networks can reduce execution risk and improve scalability.

Commercial planning should begin before pivotal trials. Developers need clear evidence packages for payers, manufacturing cost controls, decentralized sample logistics, and region-specific access models. Because personalized therapies challenge traditional reimbursement, outcomes-based contracting and diagnostic-linked value demonstration should be evaluated early.

Research Methodology

Research methodology is developed using a structured secondary-research approach. The analysis synthesizes information from regulatory agencies, peer-reviewed oncology literature, clinical trial registries, government health programs, academic cancer center publications, and recognized scientific organizations.

Insights are evaluated for clinical relevance, technological maturity, regulatory feasibility, geographic applicability, and commercial scalability. Particular attention is given to verified developments in next-generation sequencing, personalized cancer vaccines, adoptive T-cell therapies, AI-enabled antigen prediction, biomanufacturing, and immuno-oncology combinations. The methodology emphasizes triangulation across multiple credible sources rather than reliance on a single dataset.

Conclusion

Neoantigen targeted therapies represent one of the most precise frontiers in cancer immunotherapy. The sector is advancing because sequencing, computational biology, AI, and advanced manufacturing are converging to make personalized and highly specific treatment strategies more feasible.

The next phase of leadership will depend on evidence quality, speed of manufacturing, biomarker-defined patient selection, and the ability to demonstrate durable clinical benefit. Organizations that integrate scientific rigor with scalable operations and regional access planning will be best positioned to capture long-term value in this evolving precision oncology field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neoantigen Targeted Therapies Market, by Therapy Modality

  • 7.1. Adoptive Cell Therapy
    • 7.1.1. CAR-T Cell Therapy
    • 7.1.2. T Cell Receptor (TCR) Therapy
    • 7.1.3. Tumor-infiltrating lymphocytes (TIL)
  • 7.2. Personalized Neoantigen Vaccines
    • 7.2.1. Dendritic Cell (DC) Vaccines
    • 7.2.2. DNA/ RNA-based Vaccines
    • 7.2.3. Peptide (SLP) Vaccines

8. Neoantigen Targeted Therapies Market, by Treatment Approach

  • 8.1. Combination Therapy
  • 8.2. Monotherapy

9. Neoantigen Targeted Therapies Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous

10. Neoantigen Targeted Therapies Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Neoantigen Targeted Therapies Market, by Target Disease Indication

  • 11.1. Bone Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Gynecological Cancer
  • 11.4. Non-Small Cell Lung Cancer
  • 11.5. Renal Cell Carcinoma

12. Neoantigen Targeted Therapies Market, by End-User

  • 12.1. Academic & Government Research Institutes
  • 12.2. Hospitals & Clinics
  • 12.3. Specialty Clinics

13. Neoantigen Targeted Therapies Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Neoantigen Targeted Therapies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neoantigen Targeted Therapies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Achilles Therapeutics Limited
  • 17.2. Agenus Inc.
  • 17.3. AstraZeneca plc
  • 17.4. BioNTech SE
  • 17.5. Bristol-Myers Squibb Company
  • 17.6. CureVac N.V.
  • 17.7. Eli Lilly and Company
  • 17.8. EpiVax, Inc.
  • 17.9. F. Hoffmann-La Roche AG
  • 17.10. Genentech, Inc.
  • 17.11. Genocea Biosciences, Inc.
  • 17.12. Gilead Sciences, Inc.
  • 17.13. GlaxoSmithKline plc
  • 17.14. Gritstone bio, Inc.
  • 17.15. Immatics N.V.
  • 17.16. Immunomic Therapeutics, Inc.
  • 17.17. IOVANCE Biotherapeutics, Inc.
  • 17.18. Medigene AG
  • 17.19. Merck & Co., Inc.
  • 17.20. Moderna, Inc.
  • 17.21. Neon Therapeutics, Inc.
  • 17.22. Nykode Therapeutics
  • 17.23. Pfizer Inc.
  • 17.24. Precision Biologics
  • 17.25. Valo Therapeutics Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADOPTIVE CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADOPTIVE CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADOPTIVE CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL T CELL RECEPTOR (TCR) THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL T CELL RECEPTOR (TCR) THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL T CELL RECEPTOR (TCR) THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTES (TIL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTES (TIL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTES (TIL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED NEOANTIGEN VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED NEOANTIGEN VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED NEOANTIGEN VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DENDRITIC CELL (DC) VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DENDRITIC CELL (DC) VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DENDRITIC CELL (DC) VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA/ RNA-BASED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA/ RNA-BASED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA/ RNA-BASED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE (SLP) VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE (SLP) VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE (SLP) VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BONE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BONE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BONE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GYNECOLOGICAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GYNECOLOGICAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GYNECOLOGICAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 163. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 192. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 193. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 200. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 202. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 203. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2032 (USD MILLION